Introduction
In our laboratory, all normal dogs uniformly respond with a brisk natriuresis to an infusion of atrial natriuretic peptide (ANP),' whereas edematous dogs usually show a heterogeneous response. About half of all sodium-retaining chronic caval (TIVC) or cirrhotic dogs with ascites will respond to an ANP infusion with a brisk natriuresis whereas the remaining half will show no natriuresis whatsoever ( 1, 2) . This spectrum of heterogeneous response has also been reported for cirrhotic rats (3) , cirrhotic men (4) , and sodium-retaining bile duct-ligated dogs without ascites (5) . Such a heterogeneous response to ANP appears to be unique to this peptide, since we have demonstrated that TIVC "nonresponders" will respond normally to various diuretics active in different nephron segments (6) .
The lack oftubular sensitivity to ANP in -50% ofsodiumretaining TIVC dogs with ascites appears to be transient and therefore functional in nature, since when these nonresponders return to sodium balance (though maintaining their ascites), a normal natriuretic response to ANP reappears ( 1 ) . Despite intensive investigation ( 1, 2, 7) we have so far been unable to detect physiological variables that discriminate between natriuretic responders and nonresponders among TIVC or cirrhotic dogs. All of these experimental animals, no matter their response to ANP, appear physiologically equivalent. Moreover, in a recent series ofexperiments (8), we deliberately attempted to convert TIVC-responding dogs into nonresponders and vice versa by manipulating the intrarenal environment (e.g., catecholamine and angiotensin infusions, angiotensin and adrenergic blockade, adenosine receptor antagonism, etc.) with various pharmacological infusions calculated to either attenuate or promote ANP effects. These attempts proved unsuccessful.
Neutral endopeptidase 24:1 l (NEP 24:1 1 ) within the brush border of the proximal convoluted tubules serves as a major route for degradation of filtered ANP (9) . Recently, evidence has been adduced that endopeptidase inhibition may promote a natriuresis in animal models of sodium retention showing an attenuated response to the natriuretic effects of ANP (1O, 11) . In the present study, we have investigated the possible role of excessive endopeptidase degradation of ANP as a possible cause for the tubular insensitivity to this peptide in a population of TIVC dogs with urinary sodium retention and ascites unresponsive to pharmacological infusions ofthis potent natriuretic agent. Because kinins may also be degraded by this en-zyme system ( 12), we examined the role ofkinin availability as a possible modulator of the natriuretic effects of ANP.
Methods
A total of47 chronic conditioned dogs ofeither sex survived the procedure of thoracotomy and partial constriction of the supradiaphragmatic vena cava. These dogs were studied both in the alert, unanesthetized state or anesthetized, depending on the experimental protocols. Studies were also performed on 20 acute, unconditioned dogs of either sex selected for good health. They were also studied in the anesthetized or unanesthetized state as required. The preparation ofthe TIVC dogs was carried out under sterile conditions, using sodium thiopentone intravenous anaesthetic (20 mg/kg) as previously described in great detail for this laboratory ( 13). The animals were fully recovered, mobile, and eating by the first postoperative day. The dogs received a standard chow diet containing 45 meq Na+/d. All postoperative care was supervised by senior veterinarians from the McGill Animal Resources Centre, and all components ofthe study protocols received approval from the University Animal Utilization Ethics Committee. These dogs developed detectable ascites usually within 5-9 d and were studied shortly thereafter. When either TIVC or acute dogs were studied standing quietly in a Pavlov sling, the following procedures were used: All dogs were sedated with an atropine-xylazine mixture given intramuscularly (5) . Urine was collected by a standard washout technique through a Foley catheter inserted into the bladder. All infusions were given intravenously through polyethylene catheters placed by direct venipuncture in the saphenous or antecubital veins. Inulin and para-aminohippurate (PAH) were given at 0.5 ml/min through a PE50 catheter placed in one antecubital vein to measure GFR and renal plasma flow, respectively. All infusions were given with constant-speed infusion pumps. Clearance periods were 2 10 min in duration and were performed by the constant-infusion technique ( 13). Blood was sampled at the midpoint ofeach period from a PE 190 Several protocols were used in these studies, as follows: (a) Nine normal dogs were studied standing quietly in a Pavlov sling. After control clearance periods, ANP was infused at 75 ng/kg per min intravenous. After a 10-min waiting period, another set of clearance periods were collected. Plasma for inulin and PAH were collected at the midpoint ofeach urine collection whereas plasma for ANP levels was carefully collected as previously described ( 1, 2) [SQ 28603 ] is a highly specific antagonist of NEP 24:11 and is thought to have only weak actions on other peptidases contained within the proximal convoluted tubule brush border). After a 10-min wait, clearance studies were repeated. ANP was then reinfused at the previous dose level and, after another 10-min waiting period, a final set of three urine collections were made.
(b) This protocol was also followed in nine TIVC dogs who were deemed nonresponders to an infusion of ANP (AUN.V < 20 Aeq/min).
(c) The protocol was also followed for seven TIVC responders who showed a brisk natriuresis to ANP (AUNaV > 20 ,eq/min).
(d) The following protocols were employed in additional groups of responding TIVC dogs: (i) After the initial ANP infusion and a 90-min recovery period, aprotinin was given intravenously as a bolus of 50,000 kallikrein inhibitor units (KIU) and then infused as a constant infusion of 10,000 KIU/min to blunt the generation ofintrarenal kinins. After a 10-min wait, clearances were taken, ANP was then reinfused at previous dose levels and after another 10-min waiting period, another set ofclearance periods were taken (n = 5). (ii) A similar protocol as in (i), but a specific antagonist of the bradykinin receptor (D-Argo, Hyp3, thi5, D-Phe7, thi8) bradykinin (BKA) (IAF Biochem International, Inc., Montreal, Canada) was administered into the left renal artery at 15 ,g/kg per min after the initial ANP infusion. In separate pilot studies, it was determined that this dose administered to three normal dogs prevented the increased renal plasma flow and natriuresis of bradykinin (3 gg/kg per min) given into the left renal artery. The right kidney was used as a control. After a set of clearances, a second ANP infusion was given intravenously while the BKA was still being infused into the left renal artery (n = 4).
(e) In additional groups of nonresponding TIVC dogs, the following protocols were employed: (i) In four TIVC dogs unresponsive to an initial intravenous infusion of ANP, urodilatin was infused at 100 ng/ kg per min i.v. after a 1-h recovery period. After a 10-min wait, three clearance collections were taken. In an additional three dogs, the intravenous urodilatin was administered along with bradykinin given into the left renal artery at 3 Ag/kg per min. (ii) Four TIVC nonresponders studied in the anesthetized state were given the initial intravenous ANP infusion of 75 ng/kg per min while isotonic saline at 0.5 ml/min was infused through the left renal arterial catheter. After a 1-h recovery period, the renal arterial infusion was switched to bradykinin 3 pg/kg per min delivered at 0.5 ml/min. After obtaining three urine collections after a 1 0-min waiting period, the intravenous ANP infusion was readministered concurrent with the bradykinin. After a 10-min stabilization period, another set of urine collections were obtained. shown to prevent angiotensin II generation ( 14) . After three clearance periods, ANP was readministered concurrent with the captopril and a second set of clearances taken. In these studies, the captopril was being used as an inhibitor of intrarenal kininase II.
In additional groups ofnormal dogs, serving as controls, we administered urodilatin 100 ng/kg per min (n = 3), captopril, and ANP as above (n = 3).
Inulin was measured by an anthrone technique and PAH was measured by an autoanalyzer technique. These methods have previously been described in detail for this laboratory ( 13). Sodium in the urine and plasma was measured by flame photometry ( 13). Plasma protein and hematocrit were measured by techniques previously described ( 13). Immunoreactive ANP was analyzed in plasma and urine by techniques previously described in great detail ( 1, 2 2 20 ,ueq/min). In addition, we studied 20 normal control animals fed a similar salt diet. Fig. 1 summarizes the spectrum of natriuretic response to ANP (75 ng/kg per min intravenously) in all three populations of dogs. The profile of AUNaV was similar for both control and TIVC responding dogs whereas the TIVC nonresponders averaged an increment in urinary sodium excretion of only 2±0. 8 ,ueq/min. Table I summarizes some features ofthese TIVC dogs after they had developed urinary sodium retention and ascites some 5-9 d after surgery. All dogs were in good health with easily detectable volumes of ascites. The dogs in each TIVC group were quite similar, differing only in the natriuretic response to ANP and in baseline plasma iANP levels. The observation of a lower baseline level for plasma iANP in TIVC nonresponders has been an inconsistent finding in our laboratory ( 1, 2, 5-7), and will be commented upon further in the Discussion section.
Endopeptidase inhibition. Table II summarizes UNaV. This infusion was without effect (36±8 vs. 39±11 ueq/ min, NS). A similar lack of effect was observed in three responding and nonresponding TIVC dogs, respectively. Nonresponding TIVC dogs. The NEP inhibitor was administered to nine nonresponding TIVC dogs with sodium retention and ascites, and these data are summarized in Table III . The provision of the Squibb compound caused a significant natriuresis in all dogs that was unassociated with any increment in GFR, renal perfusion, ABP, or plasma levels of iANP. Though urinary excretion of ANP tended to rise, this change was not significant nor was the increment in FE of ANP. The rise in urinary excretion ofANP may be physiologically significant, however, since the rate of urinary excretion of ANP during the infusion ofthe NEP inhibitor just barely escaped statistical significance. When ANP was reinfused in the presence of NEP inhibition, UNaV increased still further so that AUNaV of 96±18 ,ueq/min (compared with recovery phase) clearly represented a significant natriuretic effect when compared with the initial response (AUNV = 3+0.8 ,ueq/min, P < 0.05). Plasma levels of iANP increased by 201% compared with the initial infusion, and the fractional excretion ofANP increased dramatically to 17.7±7.9%.
Responding TIVC dogs. Table IV summarizes the data for the responding TIVC dogs. Provision of NEP inhibition also spontaneously increased UNaV by -46±7 ueq/min (P < 0.05) and also magnified the ANP-induced natriuretic response (AUNaV = 280±43 compared with 211±50 ,eq/min initially, P < 0.05). The modest natriuretic effect ofNEP inhibition alone occurred with a significant increment in plasma iANP and with significant increments in the urinary excretion of this peptide. When ANP was reinfused in the presence of NEP inhibition, plasma levels increased by 287% and FE ofthe peptide increased to 9±2.6%.
Nonresponding TIVC dogs:further studies. Because of the putative role that NEP 24:11 may play in kinin catabolism ( 12) , we examined the possible role of kinins in the natriuretic response to ANP. Fig. 2 summarizes the data obtained from four nonresponding dogs when bradykinin was infused into the left renal artery before a reinfusion of ANP. Though bradykinin tended to increase urine flow and UNaV in the infused kidney, the changes were not significant. When ANP was reinfused in the presence of the kinin, the nonresponding TIVC dog was converted into a responder (AUNV = 114+1.9 ,ueq/ min compared with recovery phase [P < 0.05]). The initial changed from the initial one and was significantly (P < 0.05) less than that observed in the experimental controlateral kidney.
In four nonresponding TIVC dogs, we administered captopril intravenously in an attempt to augment intrarenal kinin availability. Fig. 3 summarizes these data. Though captopril was without effect on UNaV, GFR, or ABP (though there was a tendency for ABP to decrease), the reinfusion of ANP in the presence of captopril increased UNaV from 3.7±1.3 to 48±11
,geq/min (P < 0.05). The previous AUNaV had been 9 ,eq/ min. This natriuresis occurred despite a blood pressure value that was significantly less in this final phase than recorded in the initial control phase. When administered to three normal dogs, captopril had no effect on AUN.V (280 vs. 262 ueq/min, respectively) after an ANP infusion.
In four nonresponding TIVC dogs, the natriuretic peptide urodilatin was delivered intravenously at 100 ng/kg per min. Fig. 4 A summarizes these data. Urodilatin was unable to induce a natriuresis in these dogs, although when given to three normal dogs or to responding TIVC dogs, there was a prompt and significant natriuresis (AUNYV = 230±8 and 206±1 1 Aeq/ min, respectively). Finally, the effect of kinins on the renal response to the second messenger of ANP (cGMP) was examined in four nonresponding TIVC dogs with ascites. These data are given in Fig. 5 . As previously demonstrated (8) When the BKA was administered into the left renal artery of four TIVC responders, it was able to dramatically attenuate the natriuretic response to ANP in the experimental kidney. The natriuresis of the contralateral right kidney reappeared with an ANP reinfusion and was unchanged to that observed when the dogs were initially exposed to intravenous ANP. These data are summarized in Fig. 7 .
In three separate TIVC dogs responsive to the natriuretic effects of ANP, the BKA was administered into the left renal artery before intravenously infusing the NEP compound only. A second ANP infusion was not given. The initial natriuretic responses to ANP had been AUNaV = 52±5 (left kidney) and 49±4.7 ,geq/min (right kidney). When the NEP inhibitor was administered 90 min after cessation of the ANP infusion, AUNaV for the right kidney was 31±2.6 Aeq/min, but in the left kidney receiving the BKA, the AUNaV declined to 5±0.9 ,eq/ min compared with a recovery period (NS). Thus, the BKA was able to attenuate the natriuresis induced by NEP inhibition alone in the absence of an exogenous ANP infusion.
Finally (Table III) , and in other studies could raise GFR while not augmenting urinary sodium excretion ( 1, 2). We are thus dealing with a true dissociation of biological effects.
Though micropuncture studies have not been performed in any of our studies, we have demonstrated that filtered sodium load, 24-h sodium excretion, baseline sodium excretion in acute clearance studies, and baseline urinary sodium concentration have been equivalent for both canine populations ( 1, 2). Where we have measured UK/UNa + UK ratios, a measure for distal delivery and cation exchange ( 13, 16), we also have not detected differences between natriuretic responders and nonresponders. Thus, it seems unlikely that reduced distal deRecovery BKA BKA + ANP2 (Tables II-IV) . Since ANP is known to exert a potent inhibitory effect on conductive sodium transport when present only on the luminal side of the IMCD ( 18) , receptors must presumably exist at this site. Moreover, immunocytochemical evidence confirms that with a high degree of probability ANP receptors exist on the luminal aspect of both the cortical collecting duct and the IMCD ( 19) . As Wilkins et al. ( 1) recently speculated, these receptors, receiving a small but fairly constant amount ofnatriuretic peptide and protected from "up or down" regulation by varying plasma ANP levels, may play an important role in determining sodium handling by the collecting duct. Indeed, in our studies, the administration of a NEP inhibitor to TIVC nonresponders was able to elicit a modest natriuresis in this group independent of any change to GFR, C..., ABP, or plasma level of iANP (Table III) . Although urinary concentrations of ANP increased markedly, UVAN or FE of ANP just barely escaped statistical significance while increasing. In the remaining groups of dogs, a natriuretic effect after administration of the NEP inhibitor was associated with increments in plasma iANP, as well as significant increments in UVAN, and FE of ANP. Several groups of investigators (1 1, 20) have now suggested that intraluminal delivery of ANP to the IMCD (as opposed to the basolateral surface) may be critical in determining the magnitude of the natriuretic response.
The observation in our experiments that a natriuretic effect in TIVC dogs after administration of NEP inhibitor could occur in association with increased ANP urinary excretion, but also with a rise in plasma iANP levels (controls and TIVC responders), as well as the observation that the baseline ANP excretion was not less in TIVC nonresponders than other groups, or indeed was even higher during the initial ANP infusion than in control dogs, suggested that distal delivery of ANP was not necessarily correlated to sodium excretion in our TIVC dogs. The observation that administering NEP inhibitors to TIVC nonresponders was a potent method to induce tubular responsiveness to ANP in animals previously completely unresponsive to this peptide indeed suggested to us that excessive degradation of ANP by proximal tubular NEP 24:1 1 might be the cause of such unresponsiveness. Several laboratories ( 10, 1 1, 20, 21 ), working with dogs, humans, and rats, have now demonstrated that inhibition of NEP 24:1 1 with various compounds will indeed magnify the natriuretic response to ANP, even though changes in plasma ANP levels after such inhibition are variable.
Several observations in our laboratory suggest, however, that augmented availability ofANP may not be the entire cause for this increased natriuretic effect. Urodilatin is a peptide similar to ANP, first isolated from human urine by Schulz-Knappe et al. (22) and demonstrating potent vascular and natriuretic effects. Indeed, evidence has been presented that urodilatin may be that member of the ANP family primarily responsible for the regulation ofurinary sodium excretion (23) . Compared with ANP, it is NH2 terminally extended by four amino acids and is thought to be produced within the kidney and to be resistant to the degradative effects ofNEP 24:11 (23) . If urodilatin was infused into TIVC nonresponders, and excessive degradation of ANP by NEP 24:1 1 was an important cause for the lack of natriuresis, then urodilatin escaping enzymatic breakdown should now be associated with a significant natriuresis. Although this occurred in normal dogs and TIVC responders, this peptide was without effect in TIVC nonresponders. Indeed, a natriuretic effect was not observed until the dogs were pretreated with a renal arterial infusion ofbradykinin (Fig. 4) . Given that NEP 24:1 1 can hydrolyze other peptides viz kinins, neurotensin, endothelin, etc. ( 12), the possibility exists that the delivery ofkinins may be a determining factor for the tubular refractoriness to ANP in TIVC nonresponders. This idea receives support from the following observations. First, when captopril, an inhibitor of kininase and angiotensin-converting enzyme was infused into TIVC nonresponders, a natriuretic effect to a second infusion of ANP was observed (Fig. 3) . No magnification of a natriuretic effect was observed when captopril was given to normal controls. We have recently demonstrated that angiotensin infused into TIVC responders will not convert them into nonresponders and similarly the provision of an angiotensin antagonist, saralasin, does not convert TIVC nonresponders into responders after infusion ofANP (8) . Captopril probably achieved its effect, therefore, by increasing the availability of intrarenal kinins in TIVC nonresponders. The absence ofan effect in normal controls suggests that there exists an intrarenal availability of kinins beyond some critical level. The observation that UNaV did not increase following intravenous captopril alone despite an unchanged GFR (Fig. 3) suggests that this agent did not produce its permissive effect on ANP by augmented distal Na' delivery to the IMCD.
Second, though without effect on renal function or sodium excretion in the doses employed, bradykinin provided to TIVC nonresponders now permitted a natriuretic response to ANP where none previously could be elicited (Fig. 2) . Even more compelling were the observations that aprotinin could blunt the natriuretic effect ofANP in TIVC responders (Fig. 6 ). This agent is a nonspecific polyvalent serine protease inhibitor capable ofattenuating the effect ofseveral proteases, including glandular kallikrein, but its physiological effects have generally been ascribed to its ability to inhibit kinin generation (12) . Though without effect on kidney function in TIVC responders when administered alone, there was a dramatic decrement in AUNaV after ANP administration (299±69 vs. 92±26 ,teq/ min, P < 0.05) when aprotinin was administered concurrently.
It has previously been reported that a specific BKA can blunt the many physiological functions attributable to kinins (24, 25) . Smits et al. (24) have demonstrated in anaesthetized rats that the potentiation of the natriuretic effects of ANP by NEP inhibitors was completely abolished by the identical BKA used in our present studies. These investigators concluded, particularly since NEP inhibition did not cause plasma ANP levels to rise (when given alone or concurrently with an ANP infusion), that potentiation of the natriuretic effects of ANP by NEP inhibition involved intrarenal accumulation of bradykinin.
In our studies we observed a similar phenomenon but had sufficient NEP inhibitor to study only three dogs in this way. When the BKA was given into one renal artery of TIVC responders, there was no effect on UNaV. When the NEP inhibitor in usual doses was given intravenously, there was no increment in AUNaV for the experimental kidney (5±0.9 ,eq/min) whereas the AUNaV for the control kidney was significant (31±2.6 ,ueq/min). We also demonstrated however that when the BKA was given to responding TIVC dogs receiving exogenous ANP, the natriuresis from the experimental kidney was severely blunted whereas that of the control kidney continued unabated (Fig. 7) . Thus, in our hands, antagonism of bradykinin receptors was also capable of inhibiting a natriuretic effect when only exogenous ANP was infused, without simultaneous NEP inhibition.
This phenomenon has previously been reported by Sybertz et al. (24) . These investigators administered to rats the same bradykinin antagonist used in our studies. They observed that bradykinin played a permissive role for the natriuretic effects of ANP since the BKA inhibited the natriuretic response to both NEP inhibitors and exogenous ANP itself. Unlike our present studies, these authors found that the BKA itselfwould decrease both urine flow and urinary sodium excretion, suggesting perhaps a more important role for kinins in regulating tubular handling of sodium in this species than in dogs. Of interest as well, was that the BKA did not abolish the antihypertensive effect of ANP with or without simultaneous NEP inhibitors.
The observations obtained in the present studies would indicate that the availability ofintraluminal kinins may be a critical modulating factor for the natriuretic effects of ANP, and that both peptides must be present for a natriuretic response to be obtained after an exogenous ANP infusion or the delivery of "extra" ANP to the IMCD from the proximal tubule after NEP inhibition. Merely augmenting distal ANP delivery per se appears to be insufficient for a natriuresis to occur. Our studies with 8-Br-cGMP support this idea. Studies performed on cell suspensions prepared from the IMCD of TIVC and normal dogs indicate that the ability to generate cGMP is equivalent between these animals when exposed to ANP (8) . Nevertheless, our present study as well as previous studies (8) (Fig. 8, site 1 ). At site 2 in Fig. 8 , NEP 24:1 1 along with kinases destroy virtually all of the filtered kinins so that none leaves the proximal tubule (27) . In TIVC nonresponders, excess NEP activity at extrarenal sites could account for the diminished baseline levels of plasma iANP (Table I) . Augmented reabsorption of this peptide after NEP inhibition seems unlikely given the extensive degradation by NEP 24:11 within the brush border ofthe proximal convoluted tubule. As well, previous studies in this model ( 1, 2, 16) have shown that differences in plasma volume cannot account for differences in baseline plasma iANP levels. Though plasma levels of iANP did not rise in TIVC-NR dogs after NEP inhibition (as might be anticipated if excessive nonrenal degradation were occurring in this group), it should be noted that fractional excretion of ANP (Table III) rose more in this group than the others. This rise in urinary excretion might have limited the rise in plasma levels. In this latter group as well, excess intrarenal NEP activity could lead to diminished distal delivery of ANP compared with TIVC responders. That NEP activity is related to kinin degradation seems clear. It is now believed that NEP 24:1 1 is at least as important as kininase 11 in degrading kinins within the nephron (12) , and a recent report indicates that NEP 24:1 1 may account for 53-74% of intrarenal kinin degradation (28) . In rats, urinary kininase activity appears to be largely provided by NEP 24:1 1 (27).
At Fig. 8, site 3 Fig. 8 that kinins may play a permissive role for the actions of cGMP, at least in TIVC nonresponders.
The right panel of Fig. 8 , summarizes possible effects after NEP 24:11 inhibition. The presence of SQ 28603 at Fig. 8 , site 2 would augment the distal delivery of ANP and kinins. Since, however, kinins are thought not to reach the distal nephron from the proximal tubule normally, a lack of kinins from this source cannot be invoked as playing a role in the tubular insensitivity to ANP in TIVC nonresponders. As mentioned previously there may be a synthetic and/or degradative problem at the level of the distal nephron. This raises the possibility that the NEP inhibitor may be playing a beneficial role at Fig. 8 , site 3, as illustrated in the diagram. It has been speculated that the kallikrein-kinin system may clear ANP from prohormone at this site (23) , and this may be a determining factor.
In any event, after NEP inhibition, we postulate that increased delivery ofkinins and ANP distally to Fig. 8 , sites 4 and 5 may permit a magnified natriuresis in TIVC responders and induce a natriuresis in nonresponders as the delivery of kinins and ANP reach beyond some critical level. Since conductive and electroneutral pathways for sodium reabsorption are luminal, inhibition would presumably be at this site. Certainly bradykinin receptors ( 12) and ANP receptors ( 19) are thought to exist at this site. Our data also suggest that kinins are important for cGMP actions to occur, at least in TIVC nonresponders. That both substances viz ANP and kinins must be present together for an ANP-induced natriuresis to occur receives support from the observation that when antibodies to ANP are administered NEP inhibitors lose their natriuretic effects (31) . Although other investigators have certainly suggested and provided evidence that kinins may be important for the natriuretic effects of ANP after NEP inhibition (20, 24, 26, 30) , we believe that ours is the first such evidence collected in a model of sodium retention and ascites, where defects in kinin availability may serve as an explanation for the attenuated natriuretic effects of ANP The observation by us that NEP-induced natriuresis occurs in TIVC nonresponders in the absence of raised plasma levels of ANP but seems to be associated with increased urinary excretion ofANP supports the view that the ANP-kinin interactions are probably occurring at the luminal as opposed to the basolateral surface of the IMCD.
